Vita Therapeutics announced the completion of an oversubscribed $32 million Series A. Vita’s lead therapy, VTA-100, is currently undergoing studies for the treatment of limb-girdle muscular dystrophy. It is designed to be an autologous treatment that combines gene correction and iPSC technology to help repair and replace muscle cells.
[Vita Therapeutics]
7992332
{7992332:nan}
apa
50
1
163772
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/